MONALEESA-7 Phase 3 trial

June 4, 2020June 4, 2020

Kisqali Prolongs Overall Survival in Advanced Breast Cancer Patients with Internal Organ Metastases

News

Kisqali (ribociclib) combined with endocrine therapy prolongs the overall survival of women with HR-positive, HER2-negative, advanced or metastatic breast cancer with visceral metastases (in the soft internal organs), data from two ... Read more

June 19, 2019

Kisqali-Endocrine Therapy Combo Increases Overall Survival In Hormone Receptor-Positive Breast Cancer Patients, Study Shows

News

A combination of endocrine therapy and the targeted therapy Kisqali (ribociclib) is more effective than endocrine therapy alone at prolonging the survival of premenopausal women who have metastatic hormone receptor-positive ... Read more

July 25, 2018

Two New Indications of Kisqali Approved in US for Advanced Breast Cancers

News

Kisqali (ribociclib) now can be used in combination with an aromatase inhibitor as first-line therapy for all women with HR-positive, HER2-negative advanced or metastatic breast cancer in the United States, ... Read more

January 10, 2018

Kisqali Granted Breakthrough Therapy Status to Treat Breast Cancer in Premenopausal Women

News

The U.S. Food and Drug Administration (FDA) has granted Kisqali (ribociclib) Breakthrough Therapy designation for the treatment of premenopausal women with HR-positive, HER2-negative advanced breast cancer who have not received prior endocrine ... Read more

November 13, 2017November 13, 2017

Novartis to Request Kisqali’s Approval to Treat Premenopausal Women on Basis of Phase 3 Trial

News

Novartis plans to begin work with regulatory authorities to request that Kisqali (ribociclib) be approved as a first-line treatment for premenopausal women with HR-positive, HER2-negative advanced breast cancer. This decision ... Read more